Erythropoietin-Alpha Dosage Requirements in a Provincial Hemodialysis Population: Effect of Switching from Subcutaneous to Intravenous Administration
Background: The purpose of this initiative was to compare erythropoietin-α doses in hemodialysis patients who changed from subcutaneous to intravenous administration. The Manitoba Renal Program switched routes due to concern about erythropoietin-associated pure red cell aplasia. Methods: We compared...
Gespeichert in:
Veröffentlicht in: | Nephron. Clinical practice 2006-01, Vol.102 (3-4), p.c88-c92 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | c92 |
---|---|
container_issue | 3-4 |
container_start_page | c88 |
container_title | Nephron. Clinical practice |
container_volume | 102 |
creator | Raymond, Colette B. Collins, David M. Bernstein, Keevin N. Skwarchuk, Dan E. Vercaigne, Lavern M. |
description | Background: The purpose of this initiative was to compare erythropoietin-α doses in hemodialysis patients who changed from subcutaneous to intravenous administration. The Manitoba Renal Program switched routes due to concern about erythropoietin-associated pure red cell aplasia. Methods: We compared the erythropoie tin-α dosage requirements during subcutaneous administration (3 months pre-switch) and intravenous administration (months 4–6 post-switch). We also compared: hemoglobin, transferrin saturation (Tsat%), ferritin, and percent of patients receiving intravenous iron. The same erythropoietin-α regimen was initially used when patients were switched. Results: Of the 628 patients receiving erythropoietin-α, the data were complete for 400. The dose increased 26% (mean ± SD, 10,425 ± 7,330 vs. 13,125 ± 8,638 IU/week; p < 0.0001), despite similar hemoglobin, (mean ± SD, 11.5 ± 1.1g/dl (114.9 ± 11.2 g/l) vs. 11.3 ± 1.0 g/dl (113.5 ± 10.4 g/l); p = 0.0450) and iron parameters (Tsat 30.9%, ferritin 464 ng/ml (µg/l) vs. Tsat 28.7%, ferritin 538 ng/ml (µg/l)). For the subgroup of 84 patients who maintained target hemoglobin (10–11 g/dl or 110–120 g/l) for both periods, the dose increased 26% (mean ± SD, 8,393 ± 6,242 vs. 10,589 ± 7,049 IU/week; p < 0.0001) without a change in hemoglobin, (mean ± SD, 11.5 ± 0.3 g/dl (115.2 ± 3.0 g/l) vs. 11.5 ± 0.3 g/dl (114.9 ± 3.3 g/l); p = 0.5789). When stratified by subcutaneous dose, patients with the lowest dose (20,000 IU/week) experienced no increase (–3%). Conclusion: Overall, erythropoietin-α doses increased by 26% when patients were converted from subcutaneous to intravenous administration. |
doi_str_mv | 10.1159/000089665 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_16282700</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67682733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-befde015151825f8fbd3753567e76b6860393205e3e08ff89ce28fb8888d36413</originalsourceid><addsrcrecordid>eNpNkUtLxDAQx4Mouj4OngXJSfBQTRqbtt4WXd0FQfFxLmk72Y22SU3Slf0gfl-zdFFnDvPgN3-GGYSOKbmgNMkvSbAs5zzZQiPKOYliSsn2v3wP7Tv3TkgcU5Lvoj3K4yxOCRmh74ld-YU1nVHglY7GTbcQ-NY4MQf8DJ-9stCC9g4rjQV-smapdKVEg6fQmjokK6ccfjJd3wivjL7GEymh8thI_PKlfLVQeo6lNS1-6cuq90KD6R32Bs-0t2IJel2O61Zp5UJjLXKIdqRoHBxt4gF6u5u83kyjh8f72c34IaoYYT4qQdZAaBI8ixOZybJmacISnkLKS55xwnIWkwQYkEzKLK8gDlAWrGb8irIDdDbodtZ89uB80SpXQdMMSxY85eFOjAXwfAAra5yzIIvOqlbYVUFJsf5B8fuDwJ5uRPuyhfqP3Bw9ACcD8CHsHOwvMIz_AD3rjQg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67682733</pqid></control><display><type>article</type><title>Erythropoietin-Alpha Dosage Requirements in a Provincial Hemodialysis Population: Effect of Switching from Subcutaneous to Intravenous Administration</title><source>MEDLINE</source><source>Karger Journals Complete</source><creator>Raymond, Colette B. ; Collins, David M. ; Bernstein, Keevin N. ; Skwarchuk, Dan E. ; Vercaigne, Lavern M.</creator><creatorcontrib>Raymond, Colette B. ; Collins, David M. ; Bernstein, Keevin N. ; Skwarchuk, Dan E. ; Vercaigne, Lavern M.</creatorcontrib><description>Background: The purpose of this initiative was to compare erythropoietin-α doses in hemodialysis patients who changed from subcutaneous to intravenous administration. The Manitoba Renal Program switched routes due to concern about erythropoietin-associated pure red cell aplasia. Methods: We compared the erythropoie tin-α dosage requirements during subcutaneous administration (3 months pre-switch) and intravenous administration (months 4–6 post-switch). We also compared: hemoglobin, transferrin saturation (Tsat%), ferritin, and percent of patients receiving intravenous iron. The same erythropoietin-α regimen was initially used when patients were switched. Results: Of the 628 patients receiving erythropoietin-α, the data were complete for 400. The dose increased 26% (mean ± SD, 10,425 ± 7,330 vs. 13,125 ± 8,638 IU/week; p < 0.0001), despite similar hemoglobin, (mean ± SD, 11.5 ± 1.1g/dl (114.9 ± 11.2 g/l) vs. 11.3 ± 1.0 g/dl (113.5 ± 10.4 g/l); p = 0.0450) and iron parameters (Tsat 30.9%, ferritin 464 ng/ml (µg/l) vs. Tsat 28.7%, ferritin 538 ng/ml (µg/l)). For the subgroup of 84 patients who maintained target hemoglobin (10–11 g/dl or 110–120 g/l) for both periods, the dose increased 26% (mean ± SD, 8,393 ± 6,242 vs. 10,589 ± 7,049 IU/week; p < 0.0001) without a change in hemoglobin, (mean ± SD, 11.5 ± 0.3 g/dl (115.2 ± 3.0 g/l) vs. 11.5 ± 0.3 g/dl (114.9 ± 3.3 g/l); p = 0.5789). When stratified by subcutaneous dose, patients with the lowest dose (<5,000 IU/week) demonstrated the greatest increase (89%), and those with the highest dose (>20,000 IU/week) experienced no increase (–3%). Conclusion: Overall, erythropoietin-α doses increased by 26% when patients were converted from subcutaneous to intravenous administration.</description><identifier>ISSN: 1660-2110</identifier><identifier>EISSN: 1660-2110</identifier><identifier>DOI: 10.1159/000089665</identifier><identifier>PMID: 16282700</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Anemia - drug therapy ; Anemia - etiology ; Epoetin Alfa ; Erythropoietin - administration & dosage ; Female ; Hematinics - administration & dosage ; Humans ; Injections, Intravenous ; Injections, Subcutaneous ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - therapy ; Male ; Middle Aged ; Original Paper ; Prospective Studies ; Recombinant Proteins ; Renal Dialysis</subject><ispartof>Nephron. Clinical practice, 2006-01, Vol.102 (3-4), p.c88-c92</ispartof><rights>2006 S. Karger AG, Basel</rights><rights>2006 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c303t-befde015151825f8fbd3753567e76b6860393205e3e08ff89ce28fb8888d36413</citedby><cites>FETCH-LOGICAL-c303t-befde015151825f8fbd3753567e76b6860393205e3e08ff89ce28fb8888d36413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16282700$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raymond, Colette B.</creatorcontrib><creatorcontrib>Collins, David M.</creatorcontrib><creatorcontrib>Bernstein, Keevin N.</creatorcontrib><creatorcontrib>Skwarchuk, Dan E.</creatorcontrib><creatorcontrib>Vercaigne, Lavern M.</creatorcontrib><title>Erythropoietin-Alpha Dosage Requirements in a Provincial Hemodialysis Population: Effect of Switching from Subcutaneous to Intravenous Administration</title><title>Nephron. Clinical practice</title><addtitle>Nephron Clin Pract</addtitle><description>Background: The purpose of this initiative was to compare erythropoietin-α doses in hemodialysis patients who changed from subcutaneous to intravenous administration. The Manitoba Renal Program switched routes due to concern about erythropoietin-associated pure red cell aplasia. Methods: We compared the erythropoie tin-α dosage requirements during subcutaneous administration (3 months pre-switch) and intravenous administration (months 4–6 post-switch). We also compared: hemoglobin, transferrin saturation (Tsat%), ferritin, and percent of patients receiving intravenous iron. The same erythropoietin-α regimen was initially used when patients were switched. Results: Of the 628 patients receiving erythropoietin-α, the data were complete for 400. The dose increased 26% (mean ± SD, 10,425 ± 7,330 vs. 13,125 ± 8,638 IU/week; p < 0.0001), despite similar hemoglobin, (mean ± SD, 11.5 ± 1.1g/dl (114.9 ± 11.2 g/l) vs. 11.3 ± 1.0 g/dl (113.5 ± 10.4 g/l); p = 0.0450) and iron parameters (Tsat 30.9%, ferritin 464 ng/ml (µg/l) vs. Tsat 28.7%, ferritin 538 ng/ml (µg/l)). For the subgroup of 84 patients who maintained target hemoglobin (10–11 g/dl or 110–120 g/l) for both periods, the dose increased 26% (mean ± SD, 8,393 ± 6,242 vs. 10,589 ± 7,049 IU/week; p < 0.0001) without a change in hemoglobin, (mean ± SD, 11.5 ± 0.3 g/dl (115.2 ± 3.0 g/l) vs. 11.5 ± 0.3 g/dl (114.9 ± 3.3 g/l); p = 0.5789). When stratified by subcutaneous dose, patients with the lowest dose (<5,000 IU/week) demonstrated the greatest increase (89%), and those with the highest dose (>20,000 IU/week) experienced no increase (–3%). Conclusion: Overall, erythropoietin-α doses increased by 26% when patients were converted from subcutaneous to intravenous administration.</description><subject>Anemia - drug therapy</subject><subject>Anemia - etiology</subject><subject>Epoetin Alfa</subject><subject>Erythropoietin - administration & dosage</subject><subject>Female</subject><subject>Hematinics - administration & dosage</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Injections, Subcutaneous</subject><subject>Kidney Failure, Chronic - complications</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Paper</subject><subject>Prospective Studies</subject><subject>Recombinant Proteins</subject><subject>Renal Dialysis</subject><issn>1660-2110</issn><issn>1660-2110</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkUtLxDAQx4Mouj4OngXJSfBQTRqbtt4WXd0FQfFxLmk72Y22SU3Slf0gfl-zdFFnDvPgN3-GGYSOKbmgNMkvSbAs5zzZQiPKOYliSsn2v3wP7Tv3TkgcU5Lvoj3K4yxOCRmh74ld-YU1nVHglY7GTbcQ-NY4MQf8DJ-9stCC9g4rjQV-smapdKVEg6fQmjokK6ccfjJd3wivjL7GEymh8thI_PKlfLVQeo6lNS1-6cuq90KD6R32Bs-0t2IJel2O61Zp5UJjLXKIdqRoHBxt4gF6u5u83kyjh8f72c34IaoYYT4qQdZAaBI8ixOZybJmacISnkLKS55xwnIWkwQYkEzKLK8gDlAWrGb8irIDdDbodtZ89uB80SpXQdMMSxY85eFOjAXwfAAra5yzIIvOqlbYVUFJsf5B8fuDwJ5uRPuyhfqP3Bw9ACcD8CHsHOwvMIz_AD3rjQg</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>Raymond, Colette B.</creator><creator>Collins, David M.</creator><creator>Bernstein, Keevin N.</creator><creator>Skwarchuk, Dan E.</creator><creator>Vercaigne, Lavern M.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060101</creationdate><title>Erythropoietin-Alpha Dosage Requirements in a Provincial Hemodialysis Population: Effect of Switching from Subcutaneous to Intravenous Administration</title><author>Raymond, Colette B. ; Collins, David M. ; Bernstein, Keevin N. ; Skwarchuk, Dan E. ; Vercaigne, Lavern M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-befde015151825f8fbd3753567e76b6860393205e3e08ff89ce28fb8888d36413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anemia - drug therapy</topic><topic>Anemia - etiology</topic><topic>Epoetin Alfa</topic><topic>Erythropoietin - administration & dosage</topic><topic>Female</topic><topic>Hematinics - administration & dosage</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Injections, Subcutaneous</topic><topic>Kidney Failure, Chronic - complications</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Paper</topic><topic>Prospective Studies</topic><topic>Recombinant Proteins</topic><topic>Renal Dialysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raymond, Colette B.</creatorcontrib><creatorcontrib>Collins, David M.</creatorcontrib><creatorcontrib>Bernstein, Keevin N.</creatorcontrib><creatorcontrib>Skwarchuk, Dan E.</creatorcontrib><creatorcontrib>Vercaigne, Lavern M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nephron. Clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raymond, Colette B.</au><au>Collins, David M.</au><au>Bernstein, Keevin N.</au><au>Skwarchuk, Dan E.</au><au>Vercaigne, Lavern M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erythropoietin-Alpha Dosage Requirements in a Provincial Hemodialysis Population: Effect of Switching from Subcutaneous to Intravenous Administration</atitle><jtitle>Nephron. Clinical practice</jtitle><addtitle>Nephron Clin Pract</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>102</volume><issue>3-4</issue><spage>c88</spage><epage>c92</epage><pages>c88-c92</pages><issn>1660-2110</issn><eissn>1660-2110</eissn><abstract>Background: The purpose of this initiative was to compare erythropoietin-α doses in hemodialysis patients who changed from subcutaneous to intravenous administration. The Manitoba Renal Program switched routes due to concern about erythropoietin-associated pure red cell aplasia. Methods: We compared the erythropoie tin-α dosage requirements during subcutaneous administration (3 months pre-switch) and intravenous administration (months 4–6 post-switch). We also compared: hemoglobin, transferrin saturation (Tsat%), ferritin, and percent of patients receiving intravenous iron. The same erythropoietin-α regimen was initially used when patients were switched. Results: Of the 628 patients receiving erythropoietin-α, the data were complete for 400. The dose increased 26% (mean ± SD, 10,425 ± 7,330 vs. 13,125 ± 8,638 IU/week; p < 0.0001), despite similar hemoglobin, (mean ± SD, 11.5 ± 1.1g/dl (114.9 ± 11.2 g/l) vs. 11.3 ± 1.0 g/dl (113.5 ± 10.4 g/l); p = 0.0450) and iron parameters (Tsat 30.9%, ferritin 464 ng/ml (µg/l) vs. Tsat 28.7%, ferritin 538 ng/ml (µg/l)). For the subgroup of 84 patients who maintained target hemoglobin (10–11 g/dl or 110–120 g/l) for both periods, the dose increased 26% (mean ± SD, 8,393 ± 6,242 vs. 10,589 ± 7,049 IU/week; p < 0.0001) without a change in hemoglobin, (mean ± SD, 11.5 ± 0.3 g/dl (115.2 ± 3.0 g/l) vs. 11.5 ± 0.3 g/dl (114.9 ± 3.3 g/l); p = 0.5789). When stratified by subcutaneous dose, patients with the lowest dose (<5,000 IU/week) demonstrated the greatest increase (89%), and those with the highest dose (>20,000 IU/week) experienced no increase (–3%). Conclusion: Overall, erythropoietin-α doses increased by 26% when patients were converted from subcutaneous to intravenous administration.</abstract><cop>Basel, Switzerland</cop><pmid>16282700</pmid><doi>10.1159/000089665</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1660-2110 |
ispartof | Nephron. Clinical practice, 2006-01, Vol.102 (3-4), p.c88-c92 |
issn | 1660-2110 1660-2110 |
language | eng |
recordid | cdi_pubmed_primary_16282700 |
source | MEDLINE; Karger Journals Complete |
subjects | Anemia - drug therapy Anemia - etiology Epoetin Alfa Erythropoietin - administration & dosage Female Hematinics - administration & dosage Humans Injections, Intravenous Injections, Subcutaneous Kidney Failure, Chronic - complications Kidney Failure, Chronic - therapy Male Middle Aged Original Paper Prospective Studies Recombinant Proteins Renal Dialysis |
title | Erythropoietin-Alpha Dosage Requirements in a Provincial Hemodialysis Population: Effect of Switching from Subcutaneous to Intravenous Administration |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A39%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erythropoietin-Alpha%20Dosage%20Requirements%20in%20a%20Provincial%20Hemodialysis%20Population:%20Effect%20of%20Switching%20from%20Subcutaneous%20to%20Intravenous%20Administration&rft.jtitle=Nephron.%20Clinical%20practice&rft.au=Raymond,%20Colette%20B.&rft.date=2006-01-01&rft.volume=102&rft.issue=3-4&rft.spage=c88&rft.epage=c92&rft.pages=c88-c92&rft.issn=1660-2110&rft.eissn=1660-2110&rft_id=info:doi/10.1159/000089665&rft_dat=%3Cproquest_pubme%3E67682733%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67682733&rft_id=info:pmid/16282700&rfr_iscdi=true |